Beone Medicines Ltd. (688235.SH) has issued a notice announcing revisions to its 2026 operating performance forecast. The company now expects annual revenue for 2026 to fall between 44.9 billion yuan and 46.2 billion yuan.
This adjustment represents an upward revision from the previous forecast of 43.6 billion yuan to 45.2 billion yuan. The improved outlook is primarily attributed to the strong market leadership of BeiGene's product, Brukinsa (zanubrutinib), in the United States, along with its continued expansion across Europe and other key global markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments